高通量血液透析联合促红细胞生成素治疗维持性肾性贫血的临床评价

目的探讨高通量血液透析联合促红细胞生成素(EPO)治疗维持性肾性贫血的临床效果。方法肾性贫血患者30例,随机分为治疗组和对照组各15例,分别用高通量血液透析联合EPO治疗和低通量血液透析联合EPO治疗,疗程1年,观察两组的疗效。结果治疗组的不良反应率小于对照组(6.4%vs 66.7%,P0.05);治疗后与对照组比较,治疗组的尿素氮(BUN)、血细胞比容(Hct)明显下降,分别为(2.1±0.5)mmol/L vs(1.1±0.2)mmol/L(P0.01)及(152.6±119.1)%vs(38.8±17.2)%(P0.01),而与对照组比较,治疗组的多效蛋白(PTN)和血红蛋白(Hb)明显升高,分别为(100.6±3.8)mg/L vs(57.0±1.5)mg/L(P0.05)及(31.1±0.5)g/L vs(18.7±0.5)g/L(P0.01)。结论高通量血液透析联合EPO治疗维持性肾性贫血临床效果好、安全高。

Clinical evaluation on high-flux hemodialysis jointed with erythropoietin treatment in maintenance renal anemia

Objective To investigate the high-flux hemodialysis jointed with erythropoietin therapy to maintain clinical effects of renal anemia.Methods Thirty cases of renal anemia were randomly divided into treatment group and control group,1 5 cases,respectively in a group,high-flux and low-flux hemodialysis combined with erythropoietin therapy,after treatment for one year,the efficacy of two groups was observed.Results Adverse reaction rate in the treatment group was less than that of the control group （6.4% vs 66.7%,P 〈0.05）.Compared with the control group after treatment,Blood Urea Nitrogen （BUN）,Hematocrit （Hct） in treatment group decreased obviously, respectively （2.1±0.5）mmol/L vs （1.1±0.2）mmol/L（P〈0.01）,and （152.6±119.1）% vs （38.8±17.2）%（P〈0.01）,while the pleiotrophin（PTN）and Henoglobin（Hb）in treatment group significantly increased compared with those of control group,respectively （100.6±3.8）mg/L vs （57.0±1.5）mg/L（P〈0.05）,and （31.1±0.5）g/L vs （18.7±0.5）g/L（P 〈0.01）.Conclusion High-flux hemodialysis combined with erythropoietin treatment of renal anemia shows good clinical results for maintaining renal anemia with high security.